Diagnosis of extraskeletal myxoid chondrosarcoma in the thigh using - gene fusion: a case report by unknown
CASE REPORT Open Access
Diagnosis of extraskeletal myxoid
chondrosarcoma in the thigh using
EWSR1-NR4A3 gene fusion: a case report
Hiroki Kobayashi1, Kazutaka Kikuta1*, Tetsuya Sekita1, Michiro Susa1, Kazumasa Nishimoto1, Aya Sasaki2,
Kaori Kameyama2, Shintaro Sugita3, Tadashi Hasegawa3, Masaya Nakamura1, Morio Matsumoto1
and Hideo Morioka1
Abstract
Background: Extraskeletal myxoid chondrosarcoma is a rare soft tissue sarcoma that has unusual ultrastructural
and molecular features. However, unlike other soft tissue sarcomas, it does not have specific clinical symptoms
or radiological features, which can make its diagnosis difficult. Nevertheless, extraskeletal myxoid chondrosarcoma
has a rare gene fusion (EWSR1-NR4A3) that is useful for making a differential diagnosis.
Case presentation: A 43-year-old Japanese man presented with a soft tissue mass in his right thigh. A physical
examination and radiography revealed a large soft tissue mass. During magnetic resonance imaging, the mass
exhibited isointensity on T1-weighted images and high intensity on T2-weighted images, as well as gadolinium
enhancement at the side edge of the partition structure. Thus, we considered a possible diagnosis of a malignant
myxoid soft tissue tumor, such as myxoid liposarcoma, myxofibrosarcoma, or metastatic carcinomas, including
myoepithelial tumor and neuroendocrine tumor, and performed an incisional biopsy to make a definitive diagnosis.
The pathological findings revealed a lobulated tumor with a myxoid structure and atypical spindle-shaped cells
that created eosinophilic cord-like forms. Immunohistochemistry revealed that the tumor was positive for S-100
and negative for synaptophysin, chromogranin A, and pan keratin (AE1/AE3). The percentage of Ki-67 was 10 %
in the hot spot area. Based on these clinicopathological findings, we initially considered the possibility of a myxoid
liposarcoma, although we did not observe any lipoblasts. Therefore, we considered the possibility of an extraskeletal
myxoid chondrosarcoma. As this tumor is very rare, we searched for the EWSR1-NR4A3 gene fusion using fluorescence
in situ hybridization, which confirmed the diagnosis of extraskeletal myxoid chondrosarcoma. Positron emission
tomography-computed tomography did not identify any obvious metastases, and we performed radical resection
of our patient’s vastus medialis and femur with a 3 cm margin. After the resection, we treated his resected femur
using liquid nitrogen, and reconstructed his femur using autogenous fibula and plate fixation. No local recurrence or
metastasis was observed at the 1-year follow-up.
Conclusion: Genetic testing is useful for diagnosing extraskeletal myxoid chondrosarcoma based on the presence of
the EWSR1-NR4A3 gene fusion.
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Background
Extraskeletal myxoid chondrosarcoma (EMC) accounts
for 2.5 to 3 % of all soft tissue sarcomas, and is charac-
terized by a multinodular architecture, myxoid matrix,
and malignant chondroblasts [1]. Oliveira et al. defined
EMC as a distinct sarcoma with a chondroblastic origin
that arises from the extraskeletal soft tissues [2]. How-
ever, the histogenesis of EMC remains controversial, and
EMC is currently classified as a tumor of uncertain
differentiation in the revised version of the WHO Classi-
fication of Tumours of Soft Tissue and Bone [3]. Further-
more, EMC does not have specific clinical, imaging,
or pathological characteristics, which makes it difficult
to definitively differentiate between EMC and other
myxoid tumors. However, EMC has a rare gene
fusion, EWS RNA binding protein 1-nuclear receptor
subfamily 4, group A, member 3 (EWSR1-NR4A3),
which is useful in making a differential diagnosis [4, 5].
Therefore, we report the case of a 43-year-old man
with an EMC in his right thigh, which we definitively
diagnosed based on the presence of the EWSR1-
NR4A3 gene fusion.
Case presentation
A 43-year-old Japanese man presented with a soft tis-
sue mass in his right thigh during June 2015, which
he originally noticed in January 2015. He did not
have any relevant personal or family history, and a
physical examination revealed a hard and elastic mass
(approximate size 30 cm) that did not exhibit redness,
inflammation, or a pulse. His blood test results were
normal, and radiography revealed a large soft tissue
mass without calcification, periosteal reaction, or infil-
tration into his femur (Fig. 1). Magnetic resonance
imaging (MRI) revealed a mass with an isointense sig-
nal on T1-weighted images and a high-intensity signal
on T2-weighted images, with gadolinium enhance-
ment on the side edge of the partition structure
(Fig. 2). Computed tomography (CT) also revealed no
tumor calcification or obvious infiltration into his
femur (Fig. 3). Based on these findings, we considered
a possible diagnosis of a malignant myxoid soft tissue
tumor, such as myxoid liposarcoma, myxofibrosar-
coma, or metastatic carcinomas, including myoepithe-
lial tumor and neuroendocrine tumor, and performed
an incisional biopsy to make a definitive diagnosis.
The pathological findings revealed a lobulated tumor
with a myxoid matrix and atypical spindle-shaped
cells that created an eosinophilic cord-like structure
(Fig. 4a). We also observed that the tumor was posi-
tive for S-100 (Fig. 4b) which is mainly present in
neurons, chondrocytes, adipocytes, and pigment cells,
and negative for synaptophysin, chromogranin A, and
pan keratin (AE1/AE3). The percentage of Ki-67 was
10 % in the hot spot area (Fig. 4c). Thus, based on
the histology results, the site of occurrence, and our
patient’s age, we considered a differential diagnosis of
myxoid liposarcoma, which is composed of uniform
round-to-oval cells and lipoblasts in a prominent
myxoid matrix with delicate arborizing vasculature.
Fig. 1 Radiography reveals a soft tissue mass with no calcification or
periosteal reaction
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However, the tumor in the present case did not con-
tain the characteristic lipoblasts and capillary vascula-
ture. Thus, we also considered the possibility of an
EMC, despite its rare nature, as this diagnosis agreed
with our patient’s age, site of occurrence, and myxoid
pathology. Therefore, we performed fluorescence in
situ hybridization (FISH) to differentiate between
EMC and myxoid liposarcoma. This evaluation identi-
fied the EWSR1-NR4A3 gene fusion, which convinced
us that he had an EMC (Fig. 5). We also performed
systemic positron emission tomography-CT, which did
not identify any obvious metastases (Fig. 6). The
tumor was classified as TNM stage IIb, and we per-
formed extensive resection of his tumor (Fig. 7) and
femur with a 3 cm margin, as the tumor was in
contact with his femur. His femur was treated using
liquid nitrogen, and reconstructed using autogenous
fibula and internal plate fixation (Fig. 8). Our patient
was free from recurrence and metastases at the 1-
year follow-up.
Discussion
In the present case, we observed an EMC that arose
in the deep soft tissues of our patient’s right thigh.
The lower extremities are a typical location for this
lesion, and other reports have also described EMCs
occurring in the finger, hip joint, head, neck, chest
wall, and abdominal wall [6, 7]. Furthermore, previous
reports have indicated that EMCs are typically indo-
lent and associated with long-term survival (even in
cases of metastatic disease), although aggressive clin-
ical courses are occasionally observed. The risk fac-
tors for a poor clinical outcome are a large tumor
size (>10 cm), anaplasia, and high mitotic activity [8].
The tumor in the present case had a diameter of
approximately 30 cm, which suggests that it was
probably an aggressive tumor. Unfortunately, the roles
of chemotherapy and radiotherapy for EMC are poorly de-
fined; ifosfamide-based regimens or doxorubicin-based
regimens are not considered effective, although radiother-
apy may be beneficial in the adjuvant setting or as pallia-
tive treatment for metastatic disease. Thus, we performed
extensive resection of the vastus medialis and femur,
which resulted in our patient being recurrence-free at
the 1-year follow-up, although close long-term follow-
up is necessary to confirm that this treatment pro-
vided long-term efficacy. Therefore, an early accurate
diagnosis and complete resection are important for
curing cases of EMC [9].
The difficulty in definitively diagnosing EMC is re-
lated to differentiating between EMC and other myx-
oid soft tissue sarcomas, such as myxofibrosarcoma,
myxoid liposarcoma, and metastatic carcinomas, in-
cluding myoepithelial tumor and neuroendocrine
Fig. 3 Computed tomography reveals a tumor without calcification
or femur infiltration
Fig. 2 Magnetic resonance imaging findings. a T1-weighted axial imaging reveals a soft tissue tumor with an isointense signal. b T2-weighted
axial imaging reveals a soft tissue tumor with a high-intensity signal. c Axial imaging with gadolinium enhancement at the side edge of the
partition structure
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tumor, as EMCs do not have specific clinical charac-
teristics. In most cases, the tumor arises as a single
slow-growing soft tissue lesion that has a diameter of
approximately 5 to 10 cm [10]. During CT, EMCs
appear as soft tissue masses with lobular contours,
although there are no characteristic radiological fea-
tures that can differentiate EMC from other malig-
nancies [10]. The present case highlights these
nonspecific features, as the tumor gradually grew to
a diameter of 30 cm in his right thigh, although CT
did not reveal any obvious femur infiltration and
there was no qualitative evaluation of the tumor.
During MRI, it is best to use settings that can reveal
the myxoid stroma of the EMC, although EMCs do
not have any distinct MRI features because the char-
acteristic features of most myxoid tumors are soft
tissue masses with high-intensity signals on T2-
weighted images [6]. The cytological features of EMC
are round-to-oval cells that form cords in an abun-
dant and brightly metachromatic chondromyxoid
background [7]. Although EMC is considered a chon-
drosarcoma, it does not typically exhibit a cartilage
matrix, which also makes it difficult to differentiate
between EMC and other myxoid tumors. Therefore,
MRI and histopathology alone are probably insuffi-
cient to distinguish EMC from other myxoid soft
tissue tumors.
Previous reports have indicated that there is an EMC-
specific gene fusion, as approximately two-thirds of
EMCs harbor the chromosomal reciprocal translocation
of t(9;22)(q22;q12) [11], which is the fusion of the
EWSR1 gene to the NR4A3 gene [4, 5]. Furthermore, the
EWSR1/NR4A3 gene fusion is the most common genetic
event in EMC, as it occurs in 62 % of cases with a clas-
sical morphology [12]. In this context, FISH is consid-
ered the most useful genetic test for non-skeletal lesions,
based on their heterogeneous cell populations and
karyotypic variability [13]. The present case also con-
firms the usefulness of FISH for non-skeletal lesions, as
we were able to make a definitive diagnosis of EMC
based on the detection of the EWSR1-NR4A3 gene
fusion. Therefore, it is probably appropriate to perform
genetic testing for the EWSR1-NR4A3 gene fusion in
cases of suspected EMC.
Fig. 4 Pathological and immunohistochemical findings. a Hematoxylin and eosin staining (×200). b Immunohistochemistry reveals positive
expression of S-100. c Immunohistochemistry reveals that the percentage of Ki-67 was 10 % (×200)
Fig. 5 Fluorescence in situ hybridization with two split signals
(EWSR1 and NR4A3). Both of EWSR1 and NR4A3 split signals showed
a pair of split (arrow) and fused (arrow head) patterns of red and
green dyes. We counted 50 nuclei of tumor cells and they were
assessed as positive if more than 10 % of tumor cells showed split
signals. a With EWSR1, the split signal was detected in 44/50 (88 %)
of the tumor cells. b With NR4A3, the split signal was detected in
47/50 (94 %) of the tumor cells
Fig. 6 a Positron emission tomography-computed tomography
reveals no obvious distant metastases. b An axial image with the
maximum standardized uptake value of 3.1 (at the crosshairs)
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Conclusions
In the present case, we suspected EMC because of find-
ings from various examinations, and used genetic testing
to definitively diagnose EMC in our patient’s right thigh
based on the presence of the EWSR1-NR4A3 gene
fusion. Our patient has remained recurrence-free for 1-
year after extensive resection, although long-term
follow-up is necessary to confirm the efficacy of this
treatment. Therefore, genetic testing should be consid-
ered in similar cases, as the definitive diagnosis of EMC
is complicated by the absence of specific clinical
characteristics.
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